ILMN Stock Recent News

While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Illumina on Thursday forecast its annual core business revenue to be nearly flat compared to fiscal year 2023 as subdued demand for its genetic testing tools and diagnostics products extends into this year.

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?

Illumina's (ILMN) fourth-quarter 2023 results are likely to reflect the impacts of the adoption of its new generation of distributed liquid biopsy assay.

The beaten-down stock got a couple of analyst upgrades. Illumina also confirmed it would sell Grail, its controversial 2021 acquisition.

Illumina (ILMN) aims to work with other pharmaceutical industry leaders to enhance and expand the utility of its WGS MRD assay.

'Mad Money' host Jim Cramer looks back at last year's worst performers on the Nasdaq.

Investors are optimistic about Illumina's (ILMN) strength in the genomics market and strong solvency position.

SAN DIEGO , Dec. 19, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 Presentation at 9:00am Pacific Time (12:00pm Eastern Time) immediately followed by a Q&A Session to begin at approximately 9:20am Pacific Time (12:20pm Eastern Time) The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com.

The saga over DNA sequencing firm Illumina Inc.'s (ILMN) controversial purchase of cancer diagnostic test maker GRAIL appears to be over.